gbola amusa md cfa head hc research
sale trade et
sale trade et
share mil
creat bluematrix
initi buy
solut retin diseas
initi coverag buy rate
potenti achiev extend durabl
better vs exist therapi retin diseas kodiak
scienc clinical-stag biopharmaceut compani develop novel
therapeut treat high-preval ophthalm diseas compani
complet phase ia clinic trial shown sustain vision
gain week singl treatment promis
data present recent angiogenesi meet
anticip posit phase data ahead
make kodiak scienc chardan top pick
kodiak boldli test market-lead eylea
importantli kodiak plan start import head-to-head trial
pivot trial design test dose
interv market-lead eylea aflibercept dose
interv trial anticip start includ global phase ii trial
treatment-nav wet earli global phase ii trial diabet
retinopathi dr includ dme phase ii trial wet
china phase ii trial dr/dme trial china
kodiak also enrol phase ib trial patient wet
diabet macular edema dme retin vein occlus rvo
built proprietari anti-vegf model forecast bn
risk-adjust sale proprietari model figur
uniqu consid gene therapi gt non-gt anti-vegf
therapi posit view base follow factor
anti-vegf therapi ophthalmolog gener bn
global sale expect increas bn
lucenti bn eylea bn togeth grew
global sale exposur retin diseas market age
better patient screen new therapi like support
compound-annual-growth-rate despit lucenti biosimilar
frequenc anti-vegf inject determin outcom
real-world anti-vegf use lower recommend see
holekamp et al studi publish juli ciulla et al confirm
unmet medic need real-world wet patient receiv
fewer anti-vegf inject experi wors visual outcom
compar patient random clinic trial
maintain key attribut approv anti-vegf
therapi antibodi base intravitr optic clear residu
optim extend durabl anim data
data phase ia clinic trial suggest
pleas refer import disclosur inform regul analyst certif found page report
improv potenc durabl standard care treatment lucenti eylea dose
inde phase ia data suggest may candid and/or dose phase ia studi
show dose-limit toxic drug-rel intraocular inflamm success dose
us would paradigm shift address unmet medic need confirm real-world studi cite
late-stag anti-vegf competit fail adequ address treatment burden reduct note
though brolucizumab novarti rate met primari endpoint non-inferior phase hawk
harrier trial wet patient treat consist sustain dose novarti
expect obtain approv dose although allergan unrat hope file abicipar pegol
non-inferior data problem ocular inflamm far limit abicipar potenti
kodiak platform creat seri long-term strateg option us abil kodiak antibodi
biopolym conjug platform deliv promis enhanc durabl bioavail ocular tissu
support far phase ia data note large-market opportun explor
preclin dme uveiti resist wet dri
start global phase ii head-to-head studi eylea wet
chines ind submiss phase ii trial wet possibl start
chines ind submiss phase ii trial dme/dr possibl start
start global phase ii head-to-head studi eylea dr/dme
competit fda approv brolucizumab wet
present phase ia ib studi data medic meet asr
interim data global phase ii trial eylea wet
interim data chines phase ii trial eylea wet
interim data chines phase ii trial eylea dr/dme
final data global phase ii trial eylea wet
final data chines phase ii trial eylea wet
final data chines phase ii trial eylea dr/dme
interim data global phase ii trial eylea dr/dme
final data global phase ii trial eylea dr/dme
price target base probability-adjust model key franchis use dcf
wacc perpetu growth impli termin ebitda multipl deriv price target
wet diabet eye diseas npv/share model anti-vegf agent non-gene-therapi
gene therapi penetr us ophthalmolog market advanc dr/dme and/or rvo
anti-vegf agent non-gt agent thu use million patient million patient
use cumul approxim patient assum use
million patient patient averag yearli price yield million
us sale global billion sale
pipelin npv/share make vari assumpt kodiak
pipelin candid dme uveiti resist wet dri
preclin discoveri phase candid
net cash npv/share estim kodiak cash posit stood mm novemb
risk achiev target price
platform risk far clinical-stag asset kodiak failur clinic ultim
occur may taken indic platform non-viabl could possibl preclud develop
platform asset although earli data support platform
long-term data includ safeti still gener
page
clinic risk kodiak preclin product expos binari risk surround futur dataset
regulatori kodiak pipelin product may abl gain approv could see regulatori
delay even posit clinic data though kodiak intend use similar phase ii clinic trial design across
global us eu china studi though global trend toward regulatori harmon clinic
trial protocol requir differ regulatori agenc suffici dissimilar delay develop
commerci commerci kodiak build global sale market medic affair
infrastructur could increas cash burn way investor consid sub-optim addit success kodiak
platform reli abil kodiak and/or partner manufactur biolog sinc
molecul compos antibodi phosphorylcholine-bas biopolym potenti manufactur difficulti
one compon exist
competit potenti may larg project possibl due competit includ
gene therapi lucenti biosimilar and/or off-label avastin use note late-stag product develop
big biopharma compani includ novarti nr brolucizumab allergan unrat abicipar roch
unrat lucenti port deliveri system earlier stage develop potenti paradigm-shift gene
therapi competit exist buy meiragtx buy adverum neutral agtc neutral
threat lucenti biosimilar us eu patent expir respect believ limit due
exist off-label use avastin perhap versu eylea lucenti
intellectu properti per file kodiak issu us patent expir date rang
would extend patent issu kodiak pend patent applic patent hold
least termin valuat kodiak would advers affect
financ risk compani may need rais addit capit prior achiev profit accomplish
via equiti financ may result share dilut sharehold
stock price volatil share price volatil common development compani biotechnolog sector
clinical-stag biopharmaceut compani special novel therapeut treat chronic high-
preval ophthalm diseas product kodiak util antibodi biopolym conjug platform
platform design maintain potent effect drug level ocular tissu kodiak advanc product
candid anti-vegf therapi due enter global phase ii trial wet neovascular age-
relat macular degener diabet retinopathi includ diabet macular edema kodiak own world-wide
right platform use platform develop product candid includ
compani preclin bispecif bioconjug found price ipo
octob headquart palo alto california
page
chardan ophthalmolog anti-vegf model bn non-gt gt sale
chardan ophthalmolog anti-vegf model model bn risk-adjust sale
chardan ophthalmolog anti-vegf model model bn non-gt bn gt sale
catalyst kodiak gener import data throughout come year
pipelin kodiak antibodi biopolym conjug technolog platform technolog
real-world outcom show limit current anti-vegf therapi
optim size formul strength improv durabl
shown potent vitro unconjug lucenti eylea
shown bioavail vivo eylea
shown potenti extend durabl flexibl retreat window
phase ia studi single-dos shown sustain improv vision week
phase ib studi recruit test wet dme rvo patient
phase ii studi phase ii studi us/eu china dose interv
sale key product
page
chardan ophthalmolog anti-vegf model bn non-gt gt sale
figur chardan ophthalmolog anti-vegf modelw conserv model year market declin due biosimilar follow rebound new product includ
page
sale million ophthalmolog global brand anti-vegf product saleslucenti roch nv lucenti pd follow-on roch eylea bayer avastin biosimilarsbrolucizumab non-gt anti-vegf agtc targetsoth compound-annual-growth-rate compound-annual-growth-rate consensu miss hidden market valu avastin price avastin per dose rather perhap roughli per dose would make market billion
chardan ophthalmolog anti-vegf model model bn risk-adjust sale
figur chardan ophthalmolog anti-vegf modelw model billion risk-adjust sale anti-vegf therapi gener billion
page
million sale non-gene-therapi productxlucenti roch pd follow-on non-gt anti-vegf risk-adjust non-gt anti-vegf sale yoy sale anti-vegf gene therapi risk-adjust anti-vegf gene therapi sale yoy risk-adjust anti-vegf sale yoy state anti-vegf modelxpopul advanc incl ga diabet retinopathi incl dme retin vein occlus estim overlap elimin market dr/dme rvo treat anti-vegf anti-vegf non-gt biolog anti-vegf gene therapi gt share
chardan ophthalmolog anti-vegf model model bn non-gt bn gt sale
figur chardan ophthalmolog anti-vegf modelw model billion risk-adjust sale anti-vegf therapi billion come us
page
million ophthalmolog non-gene-therapi anti-vegf productsxpati non-gt anti-vegf biolog lucenti roch lucenti port deliveri system pd eylea brolucizumab non-gt anti-vegf biolog avastin biosimilar non-gt anti-vegf market product share lucenti roch share lucenti pd share eylea share brolucizumab share share non-gt biolog abicipar faricimab share avastin biosimilar year anti-vegf treatment lucenti roch lucenti port deliveri system pd eylea brolucizumab non-gt anti-vegf biolog avastin biosimilar sale non-gt anti-vegf gene therapi yoy roch pd follow-on non-gt anti-vegf ophthalmolog anti-vegf gene therapi productsxcumul patient treat anti-vegf gt patient anti-vegf gene therapi anti-vegf gt market product share share share gt share agtc gt share gt patient patient patient patient agtc gt agtc patient gt etc one-tim treatment gt sale anti-vegf gene therapi yoy kodiak scienc inc
catalyst kodiak gener import data throughout come year
figur catalyst due start global phase ii trial wet dr/dme incorpor element pivot trial design
page
dateeventchardan start global phase ii trial vs eylea treatment-nav non-inferior vs eylea design pivot ind submiss phase ii trial vs eylea wamd chinaexpect commenc ind submiss phase ii trial vs eylea dr/dme chinaexpect commenc competit file bla abicipar approv wamdthi bla file result may competit phase ii mapl data abicipar wamdus optim competit start phase trial faricimab roch wamdroch advanc asset competit pcd phase i/ii trial wamdth endpoint safeti assess week full complet nov pcd phase ia bioactiv safeti pk patient per protocol monthli start start global phase ii trial vs eylea dr/dmeexpect similar design trial wamd design pivot competit fda approv brolucizumab nv wamdu eu japan submiss plan phase ia/ib bioactiv safeti pk readout conferencesarvo may asr jul competit file ind competit initi phase ii trial mabf lucenti runway least next twelv month state novemb diabet macular edema dr diabet retinopathi gt gene therapi pcd primari complet date pd port deliveri system wamd wet neovascular age-rel macular degener
figur catalyst due report data global phase ii trial wet dr/dme incorpor element pivot trial design
page
dateeventchardan competit pcd phase ib/ii trial apelli patient multi-cent open competit pcd phase ii trial opthea patient dose-rang combo studi vs lucenti competit fda approv abicipar wamdformul issu bacteria product leav open question competit pcd kite trial brolucizumab nv patient vs eylea load dose per protocol full complet juli competit pcd kesterel trial brolucizumab nv patient vs eylea load dose per protocol full complet august interim data global trial vs eylea treatment-nav wamddesign pivot studi option administr interim interim data china trial vs eylea treatment-nav wamdkodiak expect administr interim analysi inform global interim data china phase ii trial vs eylea dr/dmekodiak expect administr interim analysi inform global competit plan file brolucizumab nv dmean approv wamd would like follow approv expect expiri relev lucenti us patentsth exist avastin may reduc impact lucenti competit pcd archway trial lucenti pd roch patient port deliveri system vs lucenti ivt full complet may competit pcd rhine trial faricimab roch patient faricimab vs eylea vs sham full complet juli competit pcd yosemit trial faricimab roch patient faricimab vs eylea vs sham full complet june final data global trial vs eylea treatment-nav wamddesign pivot studi option administr interim final data china trial vs eylea treatment-nav wamdkodiak expect administr interim analysi inform global final data china phase ii trial vs eylea dr/dmekodiak expect administr interim analysi inform global interim data global phase ii trial vs eylea dr/dmedesign pivot studi option administr interim final data global phase ii trial vs eylea dr/dmedesign pivot studi option administr interim analysisdm diabet macular edema dr diabet retinopathi gt gene therapi pcd primari complet date pd port deliveri system wamd wet neovascular age-rel macular degener
pipelin kodiak antibodi biopolym conjug technolog platform technolog
figur kodiak full right pipelin asset
page
product candidatenear-term milestonesww dual inhibitor antibodi biopolym bioconjug ivt resist wet neovascular kodiak mono-specif antibodi biopolym conjug ivt dri kodiak sciencesstag developmentpreclinphas anti-vegf bispecif antibodi biopolym conjug ivt dme uveitiskodiak anti-vegf antibodi biopolym conjug ivt wet neovascular start global trial treatment-nav wet ind trial china pia/ib data confer arvo asr kodiak anti-vegf antibodi biopolym conjug ivt diabet eye diseas ind trial china start global trial dr/dme pia/ib data confer arvo asr kodiak scienc kodiak scienc inc
real-world outcom show limit current anti-vegf therapi
adapt kodiak scienc februari corpor present cite holz fg et al br ophthalmol loteri et al lond chardan
figur despit bn global sale anti-vegf ocular agent real-world outcom sub-optim higher complianc eye inject associ better outcom
page
figur real-world outcom inferior clinic outcom anchor consequ lower complianc fewer anti-vegf inject
world data show patient anti-vegf patient lose vision due lack complianc patient fail receiv avastin lucenti eylea
monthli bi-monthli basi figur figur patient sub-optim treated/compli thu often lose vision start anti-vegf therapi
frequenc anti-vegf inject determin outcom see holekamp et studi publish juli ciulla et confirm real-world namd
patient unit state receiv fewer anti-vegf inject experi wors visual outcom compar patient random clinic trial
consist non-u studi
real-world anti-vegf inject rate thu often result visual declin visual gain per holz et patient receiv mean inject
year respect frequent visit inject associ greater improv visual acuiti
sinc avastin eylea effect less frequent dose durabl solut need
schmidt-erfurth et al efficaci safeti monthli versu quarterli ranibizumab treatment neovascular age-rel macular degener excit studi
page
trial lucenti kingdomnetherlandsfrancegermanyitalyvisu acuiti va etdr equiv world vs clinic trial outcom visual acuiti va function anti-vegf inject mean chang va yr mean chang va yr mean anti-vegf inject yr kodiak scienc inc
optim size formul strength improv durabl
adapt kodiak scienc februari corpor present chardan
figur optim similar approv agent key attribut anti-vegf ivt optic clear residu improv potenc durabl bioavail stabil
page
shown potent vitro unconjug lucenti eylea
adapt kodiak scienc februari corpor present chardan
figur optim similar approv agent key attribut anti-vegf ivt optic clear residu improv potenc
page
shown bioavail vivo eylea
adapt kodiak scienc februari corpor present chardan
figur optim similar approv agent anti-vegf ivt optic clear residu improv bioavail due phosphorylcholin biopolym
page
shown potenti extend durabl flexibl retreat window
adapt kodiak scienc februari corpor present chardan
figur optim similar approv agent key attribut anti-vegf ivt optic clear residu extend durabl
page
phase ia studi single-dos shown sustain improv vision week
adapt kodiak scienc februari corpor present chardan
figur phase ia singl ascend dose studi result show well toler associ rapid-onset high-magnitud improv vision week
page
phase ib studi recruit test wet dme rvo patient
adapt kodiak scienc februari corpor present chardan
figur phase ib trial evalu multipl dose treatment-nav wet dme rvo patient
page
phase ii studi phase ii studi us/eu china dose interv
adapt kodiak scienc februari corpor present chardan
figur phase ii trial incorpor pivot studi design importantli test head-to-head standard care eylea aflibercept
page
figur kodiak sciencesincom statement million except ep
sale key product
figur kodiak sciencesproduct revenu million
page
million except gener oper incom incom incom incom incom incom basic dilut ep ep size incom gener oper incom incom incom incom incom incom therapeut pre-pii anti-vegf ivt wamd pc ivt dme pipelin incl product sale yoy
figur kodiak sciencesdiscount cash flow dcf analysi million
page
million except per share net depreci capit increas work defer non-cash free cash first year cash unlev free cash period discount period discount year mid-year factor free cash valu unlev free cash pv forecast unlev free cash valu perpetu growth valu termin termin ebitda xenterpris valu per dilut assumptionswacc calculationsbal sheetdcf valu alloc product net cash fiscal year end wet fiscal year end dme project discount pipelin project discount per cash per dilut share price valu per perpetu growth market cap kodiak scienc inc
rate price target histori
creat bluematrix
rate price target histori inc
rate price target histori appli genet corpor agtc
creat bluematrix
creat bluematrix
page
rate price target histori plc
rate price target histori novarti ag nv
creat bluematrix
rate price target histori regenxbio inc
creat bluematrix
creat bluematrix
page
rate price target histori gensight biolog sight fp
rate price target histori nightstar therapeut nite
creat bluematrix
rate price target histori ophthotech opht
creat bluematrix
creat bluematrix
page
rate price target histori inc
rate price target histori inc
creat bluematrix
rate price target histori toolgen inc
creat bluematrix
distribut ratings/ib servic
creat bluematrix
page
analyst certif analyst respons cover secur report certifi view
express research report accur reflect person view compani secur analyst
respons cover secur report certifi part compens directli
indirectli relat specif recommend view contain research report
